Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday,...

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday, spurred on today by a downgrade to Perform at Oppenheimer, citing a lack of near-term catalysts for the drug maker over the near term.